Tazarotene/ulobetasol - Ortho Dermatologics

Drug Profile

Tazarotene/ulobetasol - Ortho Dermatologics

Alternative Names: DUOBRII; Halobetasol propionate/tazarotene; IDP-118; Tazarotene/halobetasol propionate; Ulobetasol/tazarotene

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dow Pharmaceutical Sciences
  • Developer Ortho Dermatologics
  • Class Antipsoriatics; Corticosteroids; Cyclopentanes; Keratolytics; Nicotinic-acids; Phenanthrenes; Pyridines; Retinoids; Small molecules
  • Mechanism of Action Retinoid X receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Plaque psoriasis

Most Recent Events

  • 18 Jun 2018 Ortho Dermatologics receives complete response letter from the US FDA for topical tazarotene/ulobetasol in the treatment of plaque psoriasis
  • 09 Apr 2018 Updated efficacy data from two phase III studies in Plaque psoriasis released by Ortho Dermatologics
  • 02 Nov 2017 FDA assigns PDUFA action date of 18/06/2018 for tazarotene/ulobetasol for Plaque psoriasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top